MY185650A - Cancer treatment with combinantion of plinabulin and taxane - Google Patents

Cancer treatment with combinantion of plinabulin and taxane

Info

Publication number
MY185650A
MY185650A MYPI2016000620A MYPI2016000620A MY185650A MY 185650 A MY185650 A MY 185650A MY PI2016000620 A MYPI2016000620 A MY PI2016000620A MY PI2016000620 A MYPI2016000620 A MY PI2016000620A MY 185650 A MY185650 A MY 185650A
Authority
MY
Malaysia
Prior art keywords
plinabulin
taxane compound
taxane
cancer treatment
combinantion
Prior art date
Application number
MYPI2016000620A
Other languages
English (en)
Inventor
Lan Huang
Original Assignee
Beyondspring Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52812462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY185650(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Inc filed Critical Beyondspring Inc
Publication of MY185650A publication Critical patent/MY185650A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2016000620A 2013-10-11 2013-10-11 Cancer treatment with combinantion of plinabulin and taxane MY185650A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Publications (1)

Publication Number Publication Date
MY185650A true MY185650A (en) 2021-05-27

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000620A MY185650A (en) 2013-10-11 2013-10-11 Cancer treatment with combinantion of plinabulin and taxane

Country Status (18)

Country Link
US (2) US10596169B2 (enExample)
EP (1) EP3076972B1 (enExample)
JP (1) JP6411523B2 (enExample)
KR (1) KR102225371B1 (enExample)
CN (1) CN105705148B (enExample)
AU (1) AU2013402794B2 (enExample)
BR (1) BR112016007946A2 (enExample)
CA (1) CA2926771C (enExample)
DK (1) DK3076972T3 (enExample)
ES (1) ES2902665T3 (enExample)
IL (1) IL244984B (enExample)
MX (1) MX384751B (enExample)
MY (1) MY185650A (enExample)
NZ (1) NZ719049A (enExample)
RU (1) RU2662298C2 (enExample)
SG (1) SG11201602637QA (enExample)
WO (1) WO2015051543A1 (enExample)
ZA (1) ZA201602380B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256130A4 (en) * 2015-02-12 2018-08-01 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
RU2728796C2 (ru) * 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
DK3334726T3 (da) * 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
CN110381938A (zh) * 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
ES2942889T3 (es) * 2017-03-13 2023-06-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina y uso de las mismas
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20200116477A (ko) * 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
AU2019378779A1 (en) * 2018-11-14 2021-06-03 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ATE374767T1 (de) 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US11285169B2 (en) 2013-03-13 2022-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Also Published As

Publication number Publication date
MX2016004441A (es) 2016-10-28
SG11201602637QA (en) 2016-05-30
CN105705148A (zh) 2016-06-22
RU2016112608A (ru) 2017-11-16
CA2926771A1 (en) 2015-04-16
CA2926771C (en) 2022-07-05
EP3076972A4 (en) 2017-12-20
WO2015051543A1 (en) 2015-04-16
EP3076972B1 (en) 2021-10-06
JP2016536352A (ja) 2016-11-24
AU2013402794A1 (en) 2016-05-12
IL244984B (en) 2022-05-01
CN105705148B (zh) 2021-03-23
JP6411523B2 (ja) 2018-10-24
ZA201602380B (en) 2022-05-25
KR102225371B1 (ko) 2021-03-10
NZ719049A (en) 2020-06-26
US20160250209A1 (en) 2016-09-01
MX384751B (es) 2025-03-14
US10596169B2 (en) 2020-03-24
AU2013402794B2 (en) 2020-02-27
WO2015051543A8 (en) 2016-04-21
IL244984A0 (en) 2016-05-31
EP3076972A1 (en) 2016-10-12
KR20160078987A (ko) 2016-07-05
US20200281921A1 (en) 2020-09-10
RU2662298C2 (ru) 2018-07-25
BR112016007946A2 (pt) 2017-09-12
DK3076972T3 (da) 2022-01-03
ES2902665T3 (es) 2022-03-29

Similar Documents

Publication Publication Date Title
MY185650A (en) Cancer treatment with combinantion of plinabulin and taxane
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2017007321A (es) Terapias de combinacion.
PH12016502066A1 (en) Methods of treating bladder cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX377729B (es) Métodos para tratamiento del melanoma.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12017550063A1 (en) Combination therapies for treating cancers
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
PH12016501407A1 (en) Treatment of neoplasia
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
HK1259026A1 (zh) 用於治疗癌症的抗趋除剂的局部递送
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
HK1229712A1 (en) Cancer treatment with combination of plinabulin and taxane